• Home
  • Welcome
  • CAD & Treatments
  • Donation
  • Resources
  • Webinar Resources
  • Register Web Series
  • Latest News & Events
  • Members
  • Specialists
  • Media
  • Clinical Trials
  • Our Stories
  • Stay In The Know
  • Medical Advisors
  • Contact Us
  • Privacy & Policies
  • E-Learning Education
  • Impact ISPOR
  • Observational Study
  • More
    • Home
    • Welcome
    • CAD & Treatments
    • Donation
    • Resources
    • Webinar Resources
    • Register Web Series
    • Latest News & Events
    • Members
    • Specialists
    • Media
    • Clinical Trials
    • Our Stories
    • Stay In The Know
    • Medical Advisors
    • Contact Us
    • Privacy & Policies
    • E-Learning Education
    • Impact ISPOR
    • Observational Study
  • Sign In
  • Create Account

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

Signed in as:

filler@godaddy.com

  • Home
  • Welcome
  • CAD & Treatments
  • Donation
  • Resources
  • Webinar Resources
  • Register Web Series
  • Latest News & Events
  • Members
  • Specialists
  • Media
  • Clinical Trials
  • Our Stories
  • Stay In The Know
  • Medical Advisors
  • Contact Us
  • Privacy & Policies
  • E-Learning Education
  • Impact ISPOR
  • Observational Study

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

RESOURCES AND WEBSITES

CAD Foundation Resources

Observational Study - Now Open For Registration

 Cold Agglutinin Disease Real World EvidENCE (CADENCE) Registry until July 21, 2024   

(3 year enrollment and 3 year follow up), from the following study sites, Austria, France, Germany, Italy, Japan, Netherlands, UK and the US. 

Find out more

CHMP recommends approval of Enjaymo

Paris, September 16, 2022. The European Medicines Agency’s (EMA) Committee for Medicinal  Products for Human Use (CHMP) has adopted a positive opinion for Enjaymo™ (sutimlimab),  recommending that the C1 protein (C1s) inhibitor be approved in the European Union (EU) for  treatment of hemolytic anemia in adult patients with cold agglutinin disease (CAD). CAD is a  rare, serious, and chronic autoimmune hemolytic anemia. 

Find out more

Enjaymo is now Approved

Introducing ENJAYMO–the first and only approved treatment in Cold Agglutinin Disease (CAD). ENJAYMO is a prescription medicine used to decrease the need for red blood cell transfusion due to the breakdown of red blood cells (hemolysis) in adults with CAD

Find out more

Newly Diagnosed Package

Here you will find information and essential questions to ask your doctor as well as  lab cards, check lists, blood test tracker and symptoms journal that you can print off the New Diagnosed Package PDF. (6 pages in total)

Find out more

Doctor Relationships

Medical researchers generally agree that people who trust their doctors and work together with them recover more quickly, have a better quality of life and are more satisfied with their treatment.

Find out more

Info for Medical Professionals

A nonprofit foundation dedicated to creating healthier lives for the CAD community of patients. 

Find out more

Possible Treatment Options

The following list describes treatments that are among the ones most regularly reported about Cold Agglutinin Disease and by the CAD patients who visit our website. This is not intended to be a comprehensive or all-inclusive list, and it may not be appropriate for your individual situation.  It is intended simply as a guide for reference and discussion.

Find out more

Clinical Trial Information

ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Find out more
PracticeUpdate for Healthcare Professionals

Welcome to PracticeUpdate - Free Online Resources

This is a FREE online resource exclusively for healthcare professionals.  Their expert editorial boards review and hand-select specialty-specific clinical information from a variety of sources add critical insights and context in many specialty areas such  

as topics on Sustained Hematologic Remission After Discontinuation of Sutimlimab Treatment in Patients With Cold Agglutinin Disease. Click Here To Join For Free

dr. BerenTSen Published Articles on CAD

July 16, 2021 - TREATMENT OF COLD AGGLUTININ DISEASE - Ashnews (pdf)Download
June 15, 2021 - Effective Treatment of CAD and CAD Syndrome with Ibrutinib (pdf)Download
April, 21, 2021 - The mutational landscape of cold agglutinin disease (pdf)Download
2021 - Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia (pdf)Download
July 23, 2020 - Cold Agglutinin Disease Revisited (pdf)Download
April 7, 2020 - New Insights in the Pathogenesis and Therapy of Cold Agglutinin Mediated Autoimmune (pdf)Download
January 1, 2020 - Cold Agglutinin Disease: Where Do We Stand, and Where Are We Going? (pdf)Download
2020 - Diagnosis and Treatment of Autoimmune Hemolytic Anemia in Adults (pdf)Download
Febuary 28, 2019 - Cold agglutinins: fending off the attack - Dr. Sigbjørn Berentsen (pdf)Download

External links and resources

The following links are provided solely as a resource for informational purposes only and are not intended to provide any medical advice, opinions or conclusions. 


Newly Diagnosed

https://rarediseases.info.nih.gov/diseases/6130/cold-agglutinin-disease  https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-rare-type-anemia 


Rituximab http://www.rituxan.com
MabThera (Rituxan, rituximab) http://www.mabthera.com   
 

Bendamustine and Rituximab - Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial 

 Sigbjørn  Berentsen et al  Google Search

https://ashpublications.org/blood/article/130/4/537/37109/Bendamustine-plus-rituximab-for-chronic-cold


Fludarabine http://www.drugs.com/mtm/fludarabine.html  

Fludaribine and Rituximab
High response rate and durable remissions following fludarabine and  rituximab combination therapy for chronic cold agglutinin disease.
Sigbjørn  Berentsen et al Google Search
https://ashpublications.org/blood/article/116/17/3180/27935/High-response-rate-and-durable-remissions 


Warm Heart Surgery for those with Cold Agglutinin Disease

http://www.ispub.com/journal/the-internet-journal-of-thoracic-and-cardiovascular-surgery/volume-3-number-2/warm-heart-surgery-for-the-patient-with-cold-agglutinins.html#


Global Genes – Rare Disease Foundation Alliance: www.globalgenes.org


NORD – National Organization for Rare Disorders in US: www.rarediseases.org


CORD - Canadian Organization Rare Disorders: info@raredisorders.ca


The Leukemia & Lymphoma Society: www.LLSociety.org


Bing Center for Waldenström’s Research/ Dana Farber/Harvard Cancer Center has some relevant information for Cold Agglutinin Disease: www.waldenstroms.com


Waldenström’s Macroglobulinemia – Research, Treatment, Support: www.stevenptreon.com/links.htm


CAD Co-occurring With Antiphospholipid Syndrome - Autoimmune hemolytic anemia (AIHA) is a greatly heterogeneous disease, with the clinical picture ranging from “mild/compensated to life-threatening anemia, depending on the antibody’s thermal amplitude, isotype and ability to fix complement, as well as on bone marrow compensation,” Barcellini and Fattizzo wrote. One of the rare manifestations of AIHA is cold agglutinin disease (CAD).  Click here for article.


Idelalisib and Obinutuzumab Combinatons shows promise.  Click here for article.


American Autoimmune Related Diseases: aarda.org


Search for “Cold Agglutinin Disease” or Autoimmune Hemolytic Anemia

PubMed www.pubmed.gov service of the U.S. National Library of Medicine and the National Institutes of Health


Merck Manual Home edition:  https://www.merckmanuals.com/home


Medline Plus: www.nlm.nih.gov/medlineplus/


Blood Journal:  www.bloodjournal.org American Society of Hematology Publication


Clinical trials database https://clinicaltrials.gov/


Autoimmunity Research Foundation:  https://autoimmunityresearch.org/ 


National Heart Lung and Blood Institute: www.nhlbi.nih.gov


American Society of Hematology: www.hematology.org


Raynaud’s Phenomenon: search www.medicineNet.com 


How blood works: http://health.howstuffworks.com/blood2.htm 


WebMD: https://www.webmd.com/


Clinical Advances in Hematology and Oncology  https://www.hematologyandoncology.net/  


2022 Exacerbation Secondary Cold Agglutinin Syndrome in the Setting of SARS-CoV-2
https://www.cureus.com/articles/76113-exacerbation-of-secondary-cold-agglutinin-syndrome-in-the-setting-of-sars-cov-2


2020 - Uncover the facts about cold agglutinin disease https://www.cadunraveled.com/
 

2019 - Cold agglutinin disease: current challenges and future prospects S. Berentsen, Alexander Röth, Ulla Randen, Bernd Jilma, Geir E TjØnnfjord

https://www.ncbi.nlm.nih.gov/pubmed/31114413
 

2019 - Cold agglutinins: fending off the attack| Blood | American Society of Hematology Blood (2019) 133 (9): 885-886
https://ashpublications.org/blood/article/133/9/885/260634/Cold-agglutinins-fending-off-the-attack  Sigbjørn  Berentsen
 

2019 - Inhibition of complement C1s improves severe hemolytic anemia in cold
agglutinin disease: a first-in-human trial Blood (2019)133 (9):893-901. https://ashpublications.org/blood/article/133/9/893/260641/Inhibition-of-complement-C1s-improves-severe  Ulrich Jäger, Shirley D’Sa et al

2019 - Novel insights into the treat of complement-mediated hemolytic anemia
https://www.ncbi.nlm.nih.gov/pubmed/31523413 Berentsen S, Hill A, Hill QA, Tvedt THA, Michael M

2018 - How I manage patients with cold agglutinin disease Br J Haematology/ Volume 181, Issue 3  Berentsen S https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.15109


 2018 – Autoimmune hemolytic anemia American Society of Hematology Edu Program Anita Hill and Quentin A. Hill  https://ashpublications.org/hematology/article/2018/1/382/277583/Autoimmune-hemolytic-anemia

2018 - Cold Agglutinin Disease: Medscape http://emedicine.com/ped/topic429.htm Salman Abdullah Ajubran, MD et al

2016 - ANX005, an Inhibitory Antibody Against C1q, Blocks Complement Activation triggered by Cold Agglutinins in Human Disease  Morie A Gertz Blood (2016) 128 (22):1265
https://ashpublications.org/blood/article/128/22/1265/96079/ANX005-an-Inhibitory-Antibody-Against-C1q-Blocks  

2015 - Safety, Tolerability and Activity of TNT009 in Healthy Volunteers and Patients With Complement Mediated Disorders (TNT009-01)
https://clinicaltrials.gov/ct2/show/NCT02502903?term=tnt009&rank=1
 

*2014 -TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins
http://bloodjournal.hematologylibrary.org/content/bloodjornal/123/26/4015.full.pdf

*Early study of Sutimlimab acknowledging the 40 CADdy Chatter Patients who donated the blood plasma samples used for this study.
 

2014 -Treatment of autoimmune hemolytic anemias http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181250/
 

2014 -Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943313/

2014 - Picture of Blood Human Anatomy by Matthew Hoffman, MD
http://www.webmd.com/heart/anatomy-picture-of-blood

Celebrate International Rare Disease Day – Annually February 28th or 29th
http://rarediseases.info.nih.gov/RareDiseaseDay.aspx


Rare Disease Day was established in 2008 to raise awareness about rare diseases which impact millions of people worldwide. It also highlights the importance of research to develop diagnostics and treatments to address unmet medical needs.  It is supported by the National Institutes of Health (NIH) Office of Rare Diseases Research, the NIH Clinical Center, the NIH Institutes and Centers, the Health Resources and Services Administration (HRSA), the Food & Drug Administration’s Office of Orphan Product Development (OOPD), the National Organization for Rare Disorders (NORD), and the Genetic Alliance. 

Copyright © 2022 Cold Agglutinin Disease Foundation - All Rights Reserved.

Privacy & Policies

Contact Us: info@cadfadvocacy.org

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept